Computational Analysis of Pathogenetic Pathways in Alzheimer’s Disease and Prediction of Potential Therapeutic Drugs

Abstract

Background. Alzheimer’s disease (AD) is a chronic and progressive neurodegenerative disease which affects more than 50 million patients and represents 60–80% of all cases of dementia. Mutations in the APP gene, mostly affecting the γ-secretase site of cleavage and presenilin mutations, have been identified in inherited forms of AD. Methods. In the present study, we performed a meta-analysis of the transcriptional signatures that characterize two familial AD mutations (APPV7171F and PSEN1M146V) in order to characterize the common altered biomolecular pathways affected by these mutations. Next, an anti-signature perturbation analysis was performed using the AD meta-signature and the drug meta-signatures obtained from the L1000 database, using cosine similarity as distance metrics. Results. Overall, the meta-analysis identified 1479 differentially expressed genes (DEGs), 684 downregulated genes, and 795 upregulated genes. Additionally, we found 14 drugs with a significant anti-similarity to the AD signature, with the top five drugs being naftifine, moricizine, ketoconazole, perindopril, and fexofenadine. Conclusions. This study aimed to integrate the transcriptional profiles associated with common familial AD mutations in neurons in order to characterize the pathogenetic mechanisms involved in AD and to find more effective drugs for AD.

Ferroptosis related genes in amyotrophic lateral sclerosis: screening for potential pharmacological targets

“…Fexofenadine, also known as antihistamine, is a commonly used anti-allergy drug in clinical practice. In 2022, a meta-analysis by Petralia et al found that fexofenadine was one of ve drugs that might have a potential therapeutic effect on Alzheimer's disease [17] . Chloramphenicol is an antibiotic that acts on the 50S subunit of bacterial ribosomes, blocking protein synthesis and inhibiting both gram-positive and Gram-negative bacteria.…”

Transcriptomic signatures of Aβ- and tau-induced neuronal dysfunction reveal inflammatory processes at the core of Alzheimer’s disease pathophysiology

“…The disease-oriented computational drug repurposing strategy that we present constitutes an accelerated alternative to costly drug development for AD as preliminary safety and bioavailability criteria are already established for the identified chemical compounds (Corbett et al, 2012; Mullen et al, 2016; Petralia et al, 2022). In 2021, approximately 40% of Alzheimer’s trials registered on ClinicalTrials.gov used repurposed existing medication (Cummings et al, 2021).…”

ADPurpose: identifying drug repurposing candidates for Alzheimer’s disease by single-cell RNA-sequencing and deep learning

“…Dirithromycin itself has completed Phase 1 trials for healthy subjects treatment and was used to treat many types of bacterial infections. In the contrary, dirithromycin is a predicted drug predisposed to AD according to a study that uses transcriptional profiles and in silico method to predict potential therapeutic drugs and pathogenetic pathways for AD [22].…”